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Abstract 
 
The proper expression of the epidermal growth factor receptor (EGFR) on the 
cell surface as well as its appropriate signal transduction in different organs and cell 
types is determining prenatal and postnatal development. The EGFR signaling 
network is essential for skin development and its appendages, as well as tumor 
formation and progression, respectively. EGFR is one of the key receptors in 
keratinocytes controlling proliferation, differentiation, migration and most notably 
inflammatory responses, cellular processes which play an essential role in tumor 
formation and progression. 
Due to the fact that EGFR-null mice die early after birth or during 
embryogenesis the investigation of EGFR’s function in skin inflammation and 
carcinogenesis has been difficult. However, this issue was avoided when EGFRfl/fl 
mice are crossed to K5-Cre and K5-CreERT (Indra et al., 1999)(Indra et al., 
1999)transgenic lines to generate mice, where the receptor is already deleted in the 
skin during embryogenesis (EGFRΔep), and mice, where EGFR deletion can be 
induced postnatally (EGFRΔepER). 
Epidermis-specific deletion of EGFR during embryogenesis results in both a 
delay in hair follicle cycle as well as an increased skin inflammation. I could 
demonstrate that depending on the different stages of HF cycle macrophages, 
myeloid granulocytes, monocytes and dendritic cells are significantly increased 
compared to litter mate controls. However, I could not determine a significant 
difference in the number of Langerhans cells and T-cells in the dermis and epidermis 
lacking EGFR. These findings demonstrate once more, that the expression of EGFR 
by keratinocytes is essential for inflammatory processes and loss of function causes 
chronic skin inflammation. The immune system, which acts primarily as a defense 
against injury and infection, may lead to tumor formation if it is beyond control. The 
EGFR, participating in the skin immune response, is often overexpressed in human 
carcinomas and glioblastomas. Previous studies confirmed mesenchymal-epithelial 
alterations and increased inflammation by abrogation of EGFR function in the skin. 
To address the mechanisms by which the loss of EGFR signaling pathway leads to 
increased inflammation and further on to tumor formation, TPA was applied. I 
revealed that EGFR deficiency reduces TPA-dependent hyperplasia as well as 
epidermal proliferation and apoptosis. Surprisingly, TPA-dependent ERK1/2 
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activation seems to be EGFR dependent, whereas NFκB and p38 protein activation 
seemed to be EGFR independent. Moreover, EGFR deficiency increases 
TPA-dependent attraction of monocytes, early hematopoietic dendritic progenitor 
cells, T-cells and dendritic cells. However, I could show that the basic inflammation 
found in EGFR mutants is not sufficient to induce and/or promote papillomas. 
Interestingly, in contrast to what was published before, EGFR mutant mice develop 
tumors earlier than wt controls when treated according to the 2-stage skin 
carcinogenesis model. Papillomas from EGFRΔepER mice display growth advantage 
towards those evolving in EGFRfl/fl mice in the early stages of tumor formation but 
they stop growing and enter tumor stasis at later stages. Furthermore, the 
composition of immune cell infiltrate of mutant mice in the tumor tissue as well as the 
surrounding skin is different from those in wild-type. 
In conclusion, the role of EGFR in the complex signaling network, which 
regulates the responses to influence inflammation and tumor development, was 
demonstrated. 
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Zusammenfassung 
 
Die korrekte Expression des epidermalen Wachstumsfaktorrezeptors (EGFR) 
an der Zelloberfläche ebenso wie seine Signaltransduktion  in unterschiedlichen 
Organen und Zelltypen determinieren die pränatale und postnatale Entwicklung. Das 
Signalnetzwerk des EGFR ist essentiell für die Entwicklung der Haut und ihrer 
Appendizes sowie für die Tumorentstehung und -progression. Der EGFR ist einer der 
wichtigsten Rezeptoren der Keratinozyten um die Proliferation, Differenzierung, 
Migration und vor allem Entzündungsprozesse, die eine essentielle Rolle in der 
Tumorbildung und -progression spielen, zu kontrollieren. 
Die Tatsache, dass EGFR-null Mäuse sehr früh nach der Geburt oder 
während der Embryogenese sterben, hat die Untersuchungen der Funktion des 
EGFR in Entzündungen der Haut und in der Karzinogenese erschwert. Dieses 
Problem wird jedoch umgangen, indem EGFRfl/fl Mäuse mit K5-Cre und K5-CreERT 
(Indra et al., 1999)(Indra et al., 1999)transgenen Linien gekreuzt werden um Mäuse 
zu generieren, in denen nur in der Haut der Rezeptor schon während der 
Embryogenese (EGFRΔep) deletiert ist und Mäuse, in denen die EGFR Deletion 
postnatal induziert werden kann (EGFRΔepER). 
Eine epidermal-spezifische Deletion des EGFR während der Embryogenese 
verursacht sowohl eine Verzögerung des Haarfollikelzyklus, als auch einen Anstieg 
an Entzündungsherden der Haut. Ich konnte beweisen, dass abhängig von den 
unterschiedlichen Phasen des Haarfollikelzyklus Makrophagen, myeloide 
Granulozyten, Monozyten und dendritische Zellen im Vergleich zu ihren Kontrollen 
signifikant erhöht sind. Ich konnte jedoch keinen signifikanten Unterschied der 
Langerhanszellen- und T-Zellenanzahl in der Epidermis und Dermis, denen der 
EGFR fehlt, feststellen. Diese Entdeckungen bestätigen einmal mehr, dass die 
Expression des EGFR durch Keratinozyten essentiell für Entzündungsprozesse ist 
und der Verlust seiner Funktion chronische Entzündungen der Haut verursacht. Das 
Immunsystem, primär agierend als Schutz vor Beschädigungen und Infektionen, 
könnte ohne Regulierung zur Tumorbildung führen. 
Der EGFR, der an der Immunantwort der Haut beteiligt ist, wird in humanen 
Karzinomen und Glioblastomen häufig überexprimiert. Vorherige Studien bestätigten 
mesenchymal-epitheliale Veränderungen und eine verstärkte Entzündung durch die 
Aufhebung der EGFR Funktion in der Haut. Um die Mechanismen zu beschreiben, in 
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denen der Verlust des EGFR Signalwegs zur Entzündung und weiters zur 
Tumorbildung führt, wurde TPA eingesetzt. Ich habe gezeigt, dass das Fehlen des 
EGFR sowohl die TPA-abhängige Hyperplasie, als auch die epidermale Proliferation 
und Apoptose reduziert. Widererwarten ist die TPA-mediierte Aktivierung von ERK1/2  
EGFR abhängig, wobei die Proteinaktivierung von NFκB und p38 EGFR unabhängig 
zu sein scheint. Außerdem erhöht das Fehlen des EGFR die TPA-abhängige 
Anlockung von Monozyten, frühen hämatopoietischen dendritischen Vorläuferzellen, 
T-Zellen und dendritischen Zellen. Allerdings konnte ich zeigen, dass die basale 
Entzündung in EGFR Mutanten nicht ausreicht um Papillome zu induzieren und/oder 
zu fördern. Interessanterweise, im Gegensatz zu früheren Publikationen, entwickeln 
EGFR mutante Mäuse Tumore früher als ihre Kontrollen, wenn sie nach dem 2-stage 
skin carcinogenesis Modell behandelt werden. Papillome von EGFRΔepER Mäusen 
zeigen einen Wachstumsvorteil im frühen Stadium der Tumorbildung gegenüber 
jenen, die sich in EGFRfl/fl Mäusen entwickeln, hören aber in späteren Stadien auf zu 
wachsen und gehen in eine Tumorstasis über. Zusätzlich ist die Zusammensetzung 
des Immunzelleninfilrats in mutanten Mäusen sowohl im Tumorgewebe, als auch in 
der umgebenden Haut verändert verglichen zu der des Wildtyps. 
Abschließend lässt sich sagen, dass die Rolle des EGFR in dem komplexen 
Signalnetzwerk, das die Abläufe der Entzündung und Tumorentstehung beeinflusst, 
erläutert wurde. 
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Goal of the study 
Mice lacking functional EGFR display defects in the development of the skin 
and its appendages, and fail to develop a proper hairy coat. Using different 
transgenic mouse strains, where the EGF (epidermal growth factor) receptor is 
deleted in the epidermis, I investigated whether EGFR has an impact on skin 
morphology or its immune cell composition. Furthermore, I addressed whether EGFR 
signalling is involved in the regulation of hair follicle morphogenesis and the hair 
cycle as well as the immune cell infiltration in the skin happening in this 
developmental phase. 
Moreover, I aimed elucidating if the skin inflammation induced by the lack of 
EGFR is sufficient to induce papillomas after initiation with cancerogenic agent. 
Analysing the apoptosis and proliferation rate, as well as the immune cell infiltration 
of papillomas and surrounding tissue, I investigated whether EGFR has an impact on 
tumor morphology and development. 
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Introduction 
 
1. The skin 
 
1.1 Skin development and appendages 
 
The skin is the interface of the body with the environment. The skin epidermis 
and its appendages exposed to persistent damage serve as a mechanical, chemical 
and immunological protective barrier against external influences like bacteria, 
chemical carcinogens or UV light. To perform these functions a constant process of 
self-renewal, dependent on stem cells residing in the epidermis, has to be assured. 
These stem cells have a crucial role in maintaining epidermal homeostasis, hair 
regeneration and wound healing (Fuchs and Nowak, 2008). 
 
Figure 1 ǀ Skin morphology. Cross-section through mammalian skin. 
 
The majority (95%) of the cells in the single inner (basal) layer of the 
epidermis, the so called keratinocytes, are fast dividing progeny of stem cells and 
adhere to an underlying basement membrane (BM). The BM, which separates the 
epidermis from the underlying dermis, is rich in extracellular matrix (ECM) and growth 
factors. The keratinocytes in the BM are responsible for the generation of the three 
nondividing and morphologically and biologically distinct cell layers called spinosum, 
granulosum and corneum. Undergoing a program of terminal differentiation thereby 
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moving outwards, the basal epidermal layer immaculately has to balance epidermal 
proliferation and differentiation to organize the tissue (Fuchs and Nowak, 2008). On 
the one hand, too little proliferation leads to thinning of the skin and loss of its 
function, whereas on the other hand too much proliferation may results in psoriasis or 
cancer. During embryonic development a single cell layer is formed from embryonic 
day 9.5 (E9.5) to E12.5 and further populated by mesenchymal cells, which transmit 
signals. These signals orchestrate the stratification of epidermis and the positioning 
of downgrowths that define the initiation of hair follicle (HF) morphogenesis (Blanpain 
and Fuchs, 2009). The process of stratification proceeds during E12.5 – E15.5 and is 
largely completed by E17.5. 
 In the interfollicular epidermis (IFE) specific stem cells (SCs), differing from 
those in hair follicles (HFs), are responsible for maintaining normal homeostasis (Ito 
et al., 2005; Levy et al., 2005). To date, two different models have been described to 
explain how a single layer of proliferative cells can yield a multi-layered epidermis: 
First, slow-cycling SCs differentiate in more rapidly proliferating but transiently 
amplifying (TA) cells that decrease the expression of surface integrins, like β1 and α6 
integrin, which furthermore leads to detachment and differentiation. The other model 
deals with the idea that SCs submit an asymmetric division, where β1 integrin 
regulation plays an essential role (Clayton et al., 2007; Lechler and Fuchs, 2005). 
β1 integrin is not known as a specific epidermal SC marker (Ghazizadeh and 
Taichman, 2001), however, β1 integrin-null basal cells fail to maintain proliferative 
potential in vivo (Brakebusch and Fassler, 2005). During asymmetric division, it is 
possible that SCs generate a β1-high cell, and a β1-low cell that undergoes terminal 
differentiation (Rangarajan et al., 2001). Besides keratinocytes, which are the major 
cell type in the epidermis, various specialized cells including Langerhans cells (LC), 
melanocytes (MC), Merkel cells (MKC) and lymphocytes are essential for epidermal 
homeostasis. In vitro studies showed that LCs, which have been distinguished from 
other antigen-presenting cells by the expression of langerin, are responsible for the 
uptake and the processing of lipid antigens and microbial fragments representing 
them to effector t cells (Hunger et al., 2004). Protection against UV radiation induced 
damage and skin cancer is maintained by MCs by melanin production (Lin and 
Fisher, 2007). MKCs, located in the basal layer of the epidermis and the epithelial 
sheath of hair follicle, form synaptic junctions with dermal sensory axons (Kanitakis, 
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2002).  Furthermore, lymphocytes, mainly CD8+ T cells, can be found in the stratum 
basale and stratum spinosum (Krueger and Stingl, 1989). 
In contrast to the epidermis, the dermal architecture and histology is much 
more complex. The dermis is composed of collagen, elastic tissue and reticular 
fibres. Moreover, lymphatic and vascular vessels, which play an important role in 
preserving cell migration, as well as nerves, are located in the dermis. It also contains 
many specialized cells, such as dermal DCs and plasmacytoid DCs (pDCs), CD4+ T 
helper 1 (TH1), TH2 and TH17 cells, γδ T cells and natural killer T (NKT) cells. In 
addition, macrophages, mast cells and fibroblasts are present (Nestle et al., 2009). 
Another important function of keratinocytes, besides migration and adhesion, 
is the transduction of signals from multiple pathways to regulate their proliferation 
rate. This can be mediated through the ability of intergrins to activate the Src family 
tyrosine kinases, which are activators of the Ras-mitogen-activated protein kinase 
(MAPK) signaling cascade (Lorenz et al., 2007; Schober et al., 2007). Furthermore, 
the transmembrane receptor tyrosine kinases (RTKs) for epidermal and insulin 
growth factor (EGF and IGF) have critical roles in stimulating basement membrane 
proliferation (Barrandon and Green, 1987; Scholl et al., 2007; Zenz and Wagner, 
2006). Overexpression of EGF can result in epidermal thickening (Atit et al., 2003), 
while deletion of Mig6, an antagonist of EGFR signaling, drives hyperproliferation of 
epidermal keratinocytes and consequently increases susceptibility to tumorgenesis 
(Ferby et al., 2006). Lrig1, a negative regulator of EGFR susceptibility, can repress 
keratinocyte proliferation in vitro (Jensen and Watt, 2006). β1 integrin and 
transforming growth factor α (TGFα) affect the proliferation of epidermal SCs 
positively, while TGFβ is a negative regulator that can induce G1 cyclin-dependent 
kinase (CDK) inhibitors (Massague and Gomis, 2006) as well as apoptosis. 
Furthermore, c-Myc, which is a transcription factor and target of RTK and TGFβ 
(Oskarsson et al., 2006), as well as p63, a relative of tumor suppressor p53 (Truong 
et al., 2006), control epidermal proliferation. 
Because skin is perpetually exposed to the environment, both wound repair 
and immunological response simultaneously have to proceed perfectly. Both 
processes are defined by well-regulated apoptosis and tissue degradation requiring a 
multitude of immune cells. Upon injury, initially neutrophils are attracted to 
inflammatory sites by interleukin (IL)-8, interferon gamma (IFN-γ) and C5a, then 
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monocytes, which differentiate into macrophages, and mast cells arrive from nearby 
tissue (Martin and Leibovich, 2005). Neutrophils and macrophages are very 
important because of their phagocytic function and the ability to secrete toxic 
mediators, such as ROS. Other phagocytosis-competent, myeloid cells are the 
Langerhans cells, which are elements of the adaptive immune system. Upon 
differentiation into antigen presenting cells (APC) they are responsible for antigen 
uptake, processing and presentation (Lippens et al., 2005). 
Keratinocytes play an essential role in chemotaxis of leukocytes as well as of 
themselves, and in initiation of immune defense. In vitro they express Toll-like 
receptor (TLR)1-6, 9 and 10 mRNA, although TLR3-5 and 9 appear functional and 
induce immune-associated responses (Lebre et al., 2007). Expression of TLR5 and 
9, controlled by TGF-α, result in upregulation of neutrophil-specific chemoattractant 
CXC ligand 8 (CXCL8)/ IL-8 and antimicrobial peptides (Selsted and Ouellette, 
2005). Leukocyte-derived cytokines such as TNF-α, INF-γ, IL-1, IL-17 and IL-22 not 
only induce pro-inflammatory function of keratinocyte by inducing chemokine and 
cytokine expression thereby resulting in recruitment and activation of neutrophils, 
macrophages, dendritic cell (DC) precursors and T cells in the epidermis (Pastore et 
al., 2008), but are also known as activators of EGF family growth factors and EGFR 
(Valyi-Nagy et al., 1992). 
 
1.2 Hair follicle morphogenesis and hair cycle 
 
The formation of hair follicles is a complex process depending on a well 
regulated balance between cell proliferation, polarization, differentiation and 
apoptosis.  Hair follicle morphogenesis occurs in waves from E14.5 to E 18.5 in mice, 
and starts with the formation of the hair placode, an invagination driven by 
mesenchymal-epithelial interaction (Fuchs and Nowak, 2008) and massive 
keratinocyte proliferation (Magerl et al., 2001). Induced by condensation of a specific 
set of fibroblasts the dermal papilla (DP) is formed, which drives further HF formation. 
Due to the highly proliferative and differentiating (matrix) cells at the leading front of 
the forming HF, the DP grows downwards into the dermis (Fig. 2). Moreover the inner 
root sheath (IRS) and the hair shaft (HS), originated from transiently amplifying matrix 
cells of the bulb, grow upwards. The outer root sheath (ORS) merge into the BM of 
the epidermis (Fuchs and Horsley, 2008; Fuchs and Nowak, 2008). At postnatal day 
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6 (P6) the bulb reaches the bottom of the dermis and the follicular maturation is fully 
completed. At that moment the transiently amplified matrix cells, located at the follicle 
base, continue dividing and produce progeny cells which later terminally differentiate 
to form the growing hair shaft and fibre. 
Once mature, hair follicles enter the so called hair cycle this is a tightly 
regulated process of proliferation, regression and resting. When HFs enter the so 
called hair cycle the lower portion of them regress due to an apoptosis-driven 
degenerative phase called catagen. This phase is characterized by the end of HS 
differentiation and a transformation into the so called club, which remains anchored 
during the resting phase called telogen. The first resting phase in mice begins around 
P19 and is short, lasting 1 or 2 days, however the second lasts 2 weeks. A new 
round begins with transition from telogen to anagen, when some follicle stem cells in 
the bulge region start to proliferate rapidly and differentiate. The duration of anagen 
determines the length of HS, but generally the whole HF is long and straight in 
anagen compared to the other hair cycle phases (Alonso and Fuchs, 2006). Some 
important molecular regulators are EGF, FGF5, neurotrophins, p53 and TGFβ-family 
members (Foitzik et al., 2000; Hebert et al., 1994; Schmidt-Ullrich and Paus, 2005). 
Loss of EGFR in epidermis goes hand in hand with failure of hair growth. This was 
confirmed by grafting skin or skin cells from EGFR null mice to nude mice, which 
compromise effects of systemic disease (Hansen et al., 1997). Expression of 
dominant negative EGFR in epidermis and ORS results in hair follicle morphogenesis 
arrest (Murillas et al., 1995). However, loss of TGF-α, usually expressed in the IRS 
and ORS (Luetteke et al., 1993; Nixon et al., 1996), and EGF, expressed in the ORS 
in growing hair follicles (du Cros et al., 1992), shows a less severe phenotype of curly 
whiskers and less pronounced waviness of the first hair coat. 
In WT mice during P7 and P14 EGF receptor is highly phosphorylated, 
whereas at P21, when hair follicles rest in the telogen phase the expression of EGFR 
is down regulated. At P35, when hair follicles remain in telogen the expression of 
EGFR is again down regulated. EGFR signaling is reactivated in anagen again. 
Generally EGF expression is increased a few days after birth and switched off when 
hair follicles enter catagen. Consecutive topical application of selective inhibitors of 
EGFR and ErbB2 in WT mice results in inhibition of hair growth and hair follicles are 
also stuck in anagen, confirming that EGFR/ErbB2 signaling is indispensable for hair 
growth (Mak and Chan, 2003). 
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With each new hair cycle, the resting phase expands, maybe due to the 
difficulty to achieve the threshold of stimulatory signals for telogen-to-anagen 
transition (Fuchs and Horsley, 2008). 
 
 
Figure 2 ǀ Hair follicle morphogenesis and hair cycle. After termination of hair follicle 
morphogenesis, the hair cycle is initiated by a resting phase (telogen). It continuous with a 
destructive phase (catagen) and the stem cell activating regrowth phase (anagen) again 
(Fuchs, 2007). 
 
1.3 Epidermal tumors 
 
Due to the exposure to mechanical, chemical and UV damage the risk of 
tumor development in skin is very high. The ability for selfrenewal is maintained by 
epidermal stem cells, its transient amplified progenitors and the stem cells located in 
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the hair follicle. Stem cells are the main target cells for various types of epidermal 
tumors and due to the high division rate mutations can be manifested easily. 
Furthermore, more than one event is necessary to transform a normal stem cell into a 
cancer cell (Hahn et al., 1999). The most common epithelial tumors of the skin are 
basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) in human, and 
SCCs and its precursor papillomas in mice. The most deadly form of skin cancer is 
the cutaneous melanoma. In the mouse SCC and papillomas originate from the IFE, 
while BCC is suggested to arise from undifferentiated follicle ORS due to mutations 
affecting the Hedgehog (SHH) signaling (Oro et al., 1997). Mutations in p53 and Ras 
seem to be the most important and powerful ones for the development of BCCs and 
SCCs. Although melanocytes, tightly regulated by keratinocytes, play an essential 
role in protecting the skin from UV radiation, they are the precursors of melanoma. In 
50 to 70% of melanomas BRAF, one of the three Raf genes, displays a mutation of 
valine at position 600 (V600E). This alteration results in a constitutive activation of 
ERK signaling which again stimulates proliferation and survival, and provides tumor 
growth and function (Gray-Schopfer et al., 2007). 
Genesis of epidermal tumors is not limited to genetic alteration in stem cells. 
The differentiating compartments can also be targets of alterations finally contributing 
to tumor formation. Transient amplifying cells, post-mitotic and terminally 
differentiated cells can undergo proliferation regulated by an oncogene. Moreover, 
differentiated epidermal cells affect proliferation of altered stem cells and 
consequently the creation of a tumor by enhancing or inhibiting signals (Owens and 
Watt, 2003). Many different genes are deregulated, including EGFR. Furthermore, 
molecules such as integrins, for instance, have bivalent functions. While α3β1 
integrin reduces development of papillomas into SCCs (Owens and Watt, 2001), 
α6β4 integrin leads to an enhancement of papillomas, SCCs and metastasis. β1 
integrin expression promotes an increased expression of IL-1α, which activates 
ERK/MAPK in keratinocytes. C-Myc causes vascular endothelial growth factor 
(VEGF) secretion by keratinocytes resulting in enhanced angiogenesis (Pelengaris et 
al., 1999). However, an arrest of clonal expansion is mediated by transforming 
growth factor-β (TGF-β) inhibiting epidermal proliferation (Akhurst et al., 1988). 
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2. The impact of inflammation on tumors development   
 
Tumor development is a complex multistage process initiated by genetic 
alterations. Generally these mutations drive the transformation of normal cells into 
highly malignant ones. At least two genetic changes are required to receive a 
tumorigenic competence in rodent cells, while human cells are more difficult to 
receive a malignant phenotype or genotype (Hahn et al., 1999). The most important 
criterion a genetic mutation has to fit is that cells obtain growth advantages towards 
others. In detail, the genotype of cancer cells is defined by six essential alterations in 
cell physiology regulating malignant growth (Fig. 3): self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (apoptotic) signals, evasion of programmed cell 
death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis. It is suggested that cells have to gain these alterations, but 
in random order, to become a cancer cell. However, a single genetic mutation can 
lead to more than one alteration. For instance, the loss of function mutation of the 
tumor suppressor gene p53 results both in tumor angiogenesis and resistance to 
apoptosis (Hanahan and Weinberg, 2000). 
Since the last ten years scientists postulate that the amount of the six 
capacities a cell has to achieve to transform into a cancer cell is extended by a 
seventh capacity – inflammation. Many inflammatory diseases also trigger cancer 
development which leads to the suggestion of linkage between tumorgenesis and 
inflammation. 
During the transformation, cells apparently have to develop the ability to grow 
in a chronically inflamed microenvironment, to escape immune recognition and to 
suppress immune reactivity (Cavallo et al., 2011). Both the intrinsic pathway (driven 
by genetic alteration) and extrinsic pathway (induced by inflammatory cells and 
mediators) mediate inflammation and neoplasia. Key regulators of the inflammatory 
response like cytokines, chemokines, lipid mediators, nitric oxide (NO), NFκB, HIF1α 
and STAT3 promote tumor development (Mantovani et al., 2008). Recent studies 
examined that NFκB controls macrophages polarization during tumor development 
(Hagemann et al., 2008). STAT6-/- mice harbor tumor associated macrophages 
(TAMs) displaying M1 phenotype leading to rejection of spontaneous carcinoma 
(Sinha et al., 2005). Activation of M1 phenotype by microbial products or INF-γ 
results in a high capacity of antigen presentation, secretion of IL-12 and IL-23 which 
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then provokes a type I T cell response. Furthermore, M1 macrophages display 
cytotoxic activity against tumor cells expressing NO, ROI and TNFα (Porta et al., 
2009). STAT3, an immunosuppressor and responsible for evading the immune 
system, promotes the pro-carcinogenic IL-23 expression in tumour-associated 
macrophages (Porta et al., 2009). 
 
 
Figure 3 ǀ Capabilities of Cancer. Cells 
have to gain certain skills during their 
transformation into a malignant cell 
(Hanahan and Weinberg, 2000). 
 
Furthermore, the suppression and escape from immune responses is 
mediated by tumor-associated dendritic cell with immature phenotype and recruited 
myelomonocytic cells with an alternative M2 phenotype to downregulate the adaptive 
immune response against malignant cells. Tumor-associated macrophages (TAM), 
representing the majority of inflammatory cells, and myeloid-derived suppressor cells 
(MDSC) were shown to be attracted to tumors to promote its growth, dissemination 
and metastasis. The tumor-mediated M1-M2 switch of TAMs is an essential defense. 
While M1 macrophages are cytotoxic for cancer cells, expressing certain radicals and 
TNFα, the M2 phenotype is characterized by regulation of M1 inflammation, 
promotion of adaptive Th2 immunity, angiogenesis, tissue remodeling and repair 
(Gordon and Taylor, 2005). Furthermore, M2-polarized macrophages raise killing and 
encapsulation of parasites, support wound-healing and express tumor promoting 
functions (Porta et al., 2009). MDSC, expressing CD11b and Gr-1 in mice and known 
as T cell suppressors and cancer progression promoters, are regulated by colony 
stimulating factor-1 (CSF-1), IL-6, IL-10 and VEGF.  IL-6 induces STAT3 resulting in 
a decrease of immune functions (Stewart and Trinchieri, 2009), IL-10 secreted by the 
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tumour induces the suppressive phenotype (Gallina et al., 2006) and VEGF, 
essential for the cross-talk between tumour and microenvironment, is directly 
involved in the recruitment of MDSC (Gabrilovich, 2004). 
 
3. EGFR signaling pathways 
 
The epidermal growth factor receptor (EGFR), also known as ErbB1, is the 
archetypal member of a family of four receptor tyrosine kinases which also includes 
ErbB2 (also known as HER2 or Neu), ErbB3 (HER3) and ErbB4 (HER4) (Gullick, 
2001; Yarden and Sliwkowski, 2001). These receptors are responsible for mediating 
several cellular functions, including proliferation, survival, migration, and 
differentiation. An imbalance in both one and more of these receptors plays a central 
role in the etiology and progression of solid tumors (Earp et al., 1995; Jorissen et al., 
2003). 
The EGFR, a transmembrane protein, consists of three regions, the 
extracellular ligand binding region, the intracellular region with tyrosine kinase activity 
and a transmembrane region with a single hydrophobic anchor sequence, by which 
the receptor traverses the cell membrane (Voldborg et al., 1997). Dimerization and 
phosphorylation of the EGF receptor family are the initial and essential events of 
EGF-induced signal transduction.  ErbB receptors are activated by a number of 
ligands (Fig. 4) referred to as EGF-related peptide growth factors (Riese and Stern, 
1998). Each ligand has an EGF-like domain that is sufficient to confer binding 
specificity. These include EGF itself, amphiregulin (AR) and transforming growth 
factor-α (TGFα), which bind to ErbB1, and betacellulin (BTC), heparin-binding EGF 
(HB-EGF) and epiregulin (EPR), which exhibit dual specificity in that they bind both 
ErbB1 and ErbB4. Neuregulins (NRG) comprise the third ligand family. NRG-1 and 
NRG-2 both bind ErbB3 and ErbB4, whereas the more recent additions to the NRG 
family, NRG-3 (Zhang et al., 1997) and NRG-4 (Harari et al., 1999), bind ErbB4 but 
not ErbB3. Upon activation by their cognate ligands, ErbB receptors form dimers - 
either homodimers or heterodimers. Dimerization consequently stimulates the 
intrinsic tyrosine kinase activity of the receptors and triggers autophosphorylation of 
the five specific tyrosine residues within the cytoplasmatic domain removing an 
alternate substrate/ competitive inhibitor conformation (Voldborg et al., 1997). These 
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phosphorylated residues serve as docking sites for signaling molecules involved in 
the regulation of intracellular signaling cascades (Olayioye et al., 2000). 
 
 
Figure 4 ǀ Binding 
specificities of major EGF 
family ligands to the EGFR 
family receptors. There are 
four categories of ligands that 
bind ErbB family receptors. 
EGF, AR and TGFα bind 
ErbB1; BTC, HB-EGF and EPR 
bind ErbB1 and ErbB4; NRG-1 
and NRG-2 bind ErbB3 and 
ErbB4; and NRG-3 and NRG-4 
bind ErbB4 (Olayioye et al., 
2000). 
 
Generally phosphotyrosyl residues are recognized by intracellular proteins 
containing src homology 2 motifs (SH2). These proteins that interact directly or 
indirectly include enzymes such as PLC-γ1, GAP and syp phosphotyrosine 
phosphatase, as well as non-enzymatic adapter molecules such as the p85 subunit 
of phosphoinositol 3-kinase (PI3) and the src homology and collagen (Shc) protein 
(Voldborg et al., 1997). 
The complexity of the ligands and induction of various downstream signaling 
pathways, including the Ras/MAPK, PI3K/AKT, and Jak/STAT pathway, ensure the 
specific regulation of cell proliferation, differentiation, migration and survival. 
 
3.1  MAPK/Erk pathway 
 
The mitogen-activated protein kinase pathway (MAPK), induced by EGFR, G-
protein-coupled receptors and/or integrins and transduced by small GTPases such 
as Ras, is the major pathway mediating keratinocyte survival and proliferation (Kolch, 
2000).  
Upon ligand binding and dimerization, autophosphorylation of EGFR causes 
docking of the adaptor protein Shc of GDP/GTP-exchange factor son of sevenless 
(SOS). SOS induces a conformation change of Ras by inducing an exchange of the 
bound GDP with GTP. Ras itself owns a GTPase which hydrolyses the GTP to GDP 
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when signal transduction was performed. Ras can activate Raf-1 which in turn 
phosphorylates two serine residues of MAPK/ERK kinase (MEK1/2) and after 
recruitment to the membrane MEK1/2 is activated. MEK phosphorylates extracellular 
signal-regulated kinase (ERK1/2) at threonine and tyrosine residues in its active loop. 
ERK, a serine/threonine kinase, is a subgroup of mitogen-activated proteins (MAP) 
and upon activation it can phosphorylate over 80 substrates in the cytoplasm and the 
nucleus, for instance transcription factors like Ets, Elk, c-myc or c-fos (Orton et al., 
2005). Transmission of signals is not only performed by ERK, but also via c-Jun NH2-
terminal kinase (JNK) and p38s. Generally p38 MAPKs regulate proliferation, 
differentiation, transformation and apoptosis (Weston and Davis, 2002).  
 
3.2 PI3K/ Akt pathway 
 
Another important pathway induced by EGFR is the phosphadityl inositol 3-
kinase (PI3K)/ Akt pathway, which has an impact on cell survival via inhibition of Bad 
or forkhead transcription factors, which activate apoptosis related genes, and 
regulates chemotaxis and motility (Datta et al., 1997). Furthermore, nuclear factor κB 
(NFκB)-mediated expression of prosurvival genes as well as cell growth and indirect 
activation of mammalian target of rapamycin (mTOR) is modulated by Akt activity 
(Kane et al., 1999). 
The initial step of activation of PI3K pathway is the recruitment of p85, the 
regulatory subunit of PI3K, to EGFR phosphotyrosine residues. Its catalytic subunit 
called p110 phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) at the 
3’ position of the inositol ring, and generates PIP3. PIP3 in turn mediates the 
recruitment of phosphoinositide-dependent kinase 1 (PDK1) and PDK2 to the 
membrane, resulting in phosphorylation of two residues in the Akt kinase domain for 
full activation. Phosphate and tensin homolog (PTEN) attenuates the downstream 
signaling of PI3K by removing the 3’ phosphate of PIP3 again. Akt moves to 
cytoplama and nucleus to activate NFκB, human telomerase reverse transcriptase 
(hTERT), cyclin D1, hypoxia-inducible factor (HIF)-1α, eNOS and matrix 
metalloproteinases (MMP), and to inactivate Bad, caspase 9, p27 and p21 (Dillon et 
al., 2007). 
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Figure 5 ǀ The main downstream signaling pathways controlled by EGFR (Nyati et al., 2006). 
 
3.3 STAT pathway 
 
Activation of signal transducer and activator of transcription 1 (STAT1), 
STAT3, STAT5, is mediated by a janus kinas (JAK)-dependent and JAK-independent 
mechanism. The phosphorylated EGFR initiates dimerization of STATs (Fig. 4), 
which results in translocation into the nucleus, where gene transcription was 
activated. STAT3 activation increases cell proliferation in vitro and tumour growth 
rates in vivo (Andl et al., 2004). 
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3.4 EGFR in skin development  
 
In order to maintain skin homeostasis and the controlled hair follicle growth as 
well as regression, proliferation and differentiation of epidermal cells must be strictly 
regulated. The EGFR is one of many receptors involved in maintaining skin 
development and homeostasis. In skin EGFR is expressed in the proliferation 
competent basal cells of the epidermis. However, expression is decreased as 
keratinocytes enter the program of terminal differentiation. 
The first evidence of the EGF receptor’s important role was in 1933, when 
Francis A.E. Crew postulated the mouse line waved-1 (wa-1) which habours a point 
mutation in the gene encoding TGF-α, a ligand of EGFR (FAE, 1933). These animals 
develop a curly hairy coat. Two years later, the wa-2 mice, containing a point 
mutation in the EGFR gene itself, were described and compared to wa-1 mice, wa-2 
mice display a more marked phenotype (Luetteke et al., 1994). This confirms that 
mutations in the EGF receptor obviously affect the skin development more than its 
ligands. 
Indeed, null mutations in individual ErbB loci are lethal. More specifically, 
depending upon the genetic background of the host, loss of EGFR (ErbB1) leads to 
embryonic or perinatal lethality within 3 weeks. These mice show abnormalities in 
multiple organs including the brain, skin, lung and gastrointestinal tract. EGFR-/- mice 
also show open eyelids at birth, and compromised epidermal and hair follicle 
differentiation (Miettinen et al., 1995; Sibilia et al., 1998; Sibilia and Wagner, 1995). 
Moreover EGFR-/- mice display a delay in hair follicle development and multiple hair 
shaft abnormalities, and show an aberrant wound healing response (Hansen et al., 
1997). To circumvent the high lethality of EGFR-/- in the first month, a conditional 
knock-in mouse line (hEGFRKI/KI) was generated, which live up to six months and 
express only very low levels of human EGFR in the skin. hEGFRKI/KI displays curly 
whiskers, and an altered morphology, and distribution of hair follicles. Similar to other 
mice harboring mutations in the EGFR pathway, hEGFRKI displays a strong 
infiltration, mainly macrophages, lymphocytes, neutrophils and multinucleated giant 
cells, with most likely leads to the loss of most hair follicles over time (Sibilia et al., 
2003).  
In summary, EGFR and its ligands play an important role in skin development 
and homeostasis. EGFR orchestrates proliferation and differentiation of interfollicular 
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and follicular epidermal cells. Furthermore, EGFR signaling pathway influences hair 
follicle morphogenesis and cycling. 
 
3.5 EGFR in skin cancer 
 
EGFR signaling pathways are very important for keratinocytes cell fate, 
because a modification of those pathways results in mesenchymal-epithelium 
alterations. Both EGFR overexpression and mutations have been observed in a wide 
variety of malignancies (colorectal, breast, NSCLC, pancreatic, gastric), which has 
stimulated interest in EGFR as a target for anticancer therapies. Epidermal tumors 
frequently display EGFR overexpression (Hunts et al., 1985). In contrast, loss of 
function of EGFR inhibits the development of skin tumors, confirmed by grafting 
EGFR-null keratinocytes expressing v-rasHa which results in size reduction of 
papillomas (Dlugosz et al., 1997). Moreover K5-SOS-F mice, expressing human SOS 
in the epidermis and ORS, develop spontaneous papillomas. Tumorgenic response 
is reduced in K5-SOS-F transgenic EGFR-null mice, suggesting that EGFR is 
essential for the development of skin tumors (Sibilia et al., 2000). A similar effect is 
proven when K5-SOS-F mice are crossed to wave-2 mice (Luetteke et al., 1994). In 
addition, EGFR is essential for maintaining the proliferative population in basal cell 
compartments of papillomas (Hansen et al., 2000). In addition, it was shown that 
EGFR is a survival factor for epidermal tumor cells (Sibilia et al., 2000). Furthermore, 
EGFR acts as a regulator of VEGF and Ang-1 expression accentuating the 
fundamental role in cancerogenesis (Casanova et al., 2002). The interaction of 
EGFR and VEGF has been confirmed by deletion of both one VEGF allele as well as 
both VEGF alleles in EGFRwa2/ wa2 and EGFRΔepER background. In the absence of 
EGFR and VEGF tumor development was inhibited in EGFRwa2/ wa2, and K5-SOS-
dependent tumor size was severely reduced in the epidermis suggesting that EGFR 
expression is sufficient (Lichtenberger et al., 2010). 
 
3.6 Interplay between immune system and EGFR signaling 
 
Dermatological toxicities have been described in patient treated with EGFR 
inhibitors (EGFRIs) which is a common therapy against various malignancies. Those 
29 
 
dermatologic alterations are papulopustular rash, dry skin, itching, and hair and 
periungual alterations (Lacouture, 2006). 
There is increasing evidence that the EGF receptor and its downstream 
targets are involved in immune responses of the skin. It was shown that EGFR 
inhibition can lead to the recruitment and activation of immune cells because its 
activation is responsible for down regulation of TNF-α- or INF-γ-induced 
CCL5/RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted) 
and CCL2/MCP-1 (monocyte chemotactic protein-1) expression in human 
keratinocytes. Neutrophils, monocytes/macrophages and DC precursors as well as T 
cell immigration to skin lesions is impaired upon the EGFR activation in vivo. In vitro 
experiments in epidermal keratinocytes show a severely increased level of CCL2, 
CCL5 and CCL10, and decreased level of CCL8 when EGFR or ERK is inhibited 
(Pastore et al., 2005). Furthermore, ERK or EGFR inhibition, support the function of 
antigen-presenting cells, such as Langerhans cells, by enhancing their expression of 
IL-1β (Fujita et al., 2007).  
Furthermore, upregulation of EGFR and its ligands is characteristic for chronic 
inflammatory skin disorders such as psoriasis. Suprabasal expression of 
amphiregulin causes severe psoriasis-like hyperplasia as well as dermal and 
epidermal infiltration of neutrophils and lymphocytes (Cook et al., 1997). Additionally, 
deficiency of epiregulin results in chronic dermatitis which is correlated with increased 
expression of the pro-inflammatory cytokine IL-18 by keratinocytes (Shirasawa et al., 
2004). 
The distinct function of EGFR, its ligands and downstream targets in regulation 
and interference of the immune response in skin is still an unknown field in science. 
 
4. Tumor model 
 
Chemical induction of tumors in mouse skin has been used to study 
mechanisms of epithelial carcinogenesis and evaluate modifying factor. The model of 
the multi-stage chemical carcinogenesis (Fig. 6) represents one of the best 
established in vivo models for the study of the sequential and stepwise development 
of tumors. It can be used to evaluate both novel skin cancer prevention strategies, 
the impact of genetic background and genetic manipulation on tumor initiation, 
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promotion and progression. Cell proliferation and hyperplasia, two characteristics of 
multistep evolution of cancer, influence the development of the two-stage protocol for 
mouse skin tumorgenesis (Kemp, 2005). While in other carcinogenesis protocols 
tumor development does not require treatment with promoting agents , in two-stage 
skin carcinogenesis the promotion via a tumor-promoting agent, for instance 12-O-
tetradecanoylphorbol (TPA), plays an essential role (Abel et al., 2009).  
 
 
Figure 6 ǀ Two-stage model of skin carcinogenesis in mice. Initiation of mutations in the target 
genes in keratinocyte stem cells is induced by a single topical application of a sub-carcinogenic 
dose of a mutagenic agent. During this stage, mutation in critical target genes of stem cells in the 
bulge region of the hair follicle or basal compartments of interfollicular epidermis is essential. Two 
weeks after initiation a promoting agent is regularly and topically applied. “Promotion” is 
characterized by an increased DNA synthesis and inflammation, and an expansion of the initiated 
stem cell population. Progression, the last stage of this model, is defined by additional genetic 
events such as aneuploidy, loss of heterozygosity (LOH), dysplasia, conversion of papilloma to 
squamous cell carcinoma, invasion and finally metastasis (Abel et al., 2009). 
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Tumor initiation, an irreversible step, is applied by a single sub-carcinogenic 
dose of a carcinogen such as 7,12-dimethylbenz[a]anthracene (DMBA). Keratinocyte 
stem cells, localized in the interfollicular epidermis and the bulge region, are believed 
to be the primary cellular target of the initiation stage. The single topical application of 
DMBA induces metabolic activation of procarcinogens and covalent binding to the 
DNA, inducing for instance an A to T transversion in codon 61 of the Hras1 gene 
(Brown et al., 1990). Mutations in Hras1 are observed in the majority of papillomas 
(Balmain et al., 1984). The fixation and propagation of mutations are enabled by DNA 
repair and cell replication. Tumor promotion is induced by the repeated topical 
application of chemical agents or wounding (Kemp, 2005), which stimulates cell 
signaling, induces production and release of growth factors, generates oxidative 
stress, proliferation of basal keratinocytes, increased DNA synthesis and an 
inflammatory cell infiltration leading to epidermal hyperplasia (DiGiovanni, 1992; 
Kemp, 2005). The development of papillomas was described during promotion, in a 
time span of 10 to 40 weeks after initiation. The success of two-stage skin 
carcinogenesis in mice is known to be highly dependent on genetic background 
(DiGiovanni, 1992).  Metabolizing the initiating agents, formation and removal of 
covalent DNA-adducts do not significantly differ, thus, the susceptibility lies in the 
response to the tumor promotion (Abel et al., 2009). They may progress to invasive 
squamous cell carcinomas (SCC). SCCs are downward invading lesions that are 
highly vascularized. Numerous gene expression changes are present, including 
those associated with epithelial-mesenchymal transition (EMT) (Caulin et al., 1993; 
Navarro et al., 1991). An advantage of this model is that tumor development can 
conveniently be monitored visually throughout the life span of the mouse and that 
efficacy of chemopreventive agents or the effect of dietary manipulation can be 
determined (DiGiovanni, 1991). 
 
5. EGFR mutant mouse strains used in this study 
 
To investigate the role of EGFR in skin physiology and pathology different 
EGFR mutant mouse strains were used: EGFR-/- mice show strain-dependent 
phenotypes with fatal defects in neuronal and epithelial tissues and die at different 
stages of embryonic and early postnatal development dependent on their genetic 
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background (Miettinen et al., 1995; Sibilia et al., 2007; Sibilia et al., 1998; Sibilia and 
Wagner, 1995; Threadgill et al., 1995).  
EGFRwa2/wa2 mice contain a T-to-G transversion mutation in the sequences 
encoding the tyrosine kinase domain on chromosome 11, resulting in a substitution of 
a glycine for a highly conserved valine at position 743 in the third kinase subdomain. 
The ability of wa2 EGFR to phosphorylate an exogenous substrate is reduced by 
> 90% compared with that of wild-type receptor (Luetteke et al., 1994). 
The conditional EGFR mice (EGFRfl/fl), which were generated in the laboratory 
of Dr. Sibilia (Natarajan et al., 2007) carried either floxed or flirt alleles (Fig. 7). The 
EGFR flirt allele is a floxed allele containing a Neo-cassette.  Both alleles behave the 
same and result in a delta (Δ) allele lacking the promoter and exon 1 of EGFR upon 
Cre-mediated recombination. These EGFRfl/fl mice were crossed to K5-Cre (Tarutani 
et al., 1997) and K5-CreERT (Indra et al., 1999) transgenic lines resulting in mice , 
where the receptor is constitutively deleted already during embryogenesis (EGFRΔep), 
and mice, where EGFR deletion can be induced postnatally by the injection of 
tamoxifen (EGFRΔepER). 
 
 
 
Figure 7 ǀ Generation of 
conditional alleles of EGFR. 
The EGFR flirt allele is a 
floxed allele containing a Neo-
cassette. It behaves like the 
EGFR floxed allele. Upon Cre-
mediated recombination 
exon 1, which is flanked by 
lox-P sites, is deleted. 
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Results 
 
1. EGFR∆ep mice show a delay in hair cycle and do not enter catagen 
 
Several studies in EGFR mutant mice have shown that EGFR signaling plays 
an important role during hair follicle morphogenesis and HF cycling (Mak and Chan, 
2003). However, as EGFR k.o. mice die shortly after birth, a detailed analysis could 
not be performed. Therefore, I addressed the effect of epidermis-specific EGFR 
deletion in EGFRΔep mice at different phases of the hair cycle. Histological analysis of 
skin sections revealed that HF length is different in EGFRΔep. While at P8 HFs of 
EGFRfl/fl mice obtain 650μm, HFs of mice lacking EGFR in epidermis reaches only 
half of that size and at P10, when HF are fully developed, HF from EGFRΔep mice  
only reach 77,43% of the length of wt controls (Fig. 8A). In addition, the analysis 
demonstrates that the lack of epidermal EGFR prevents HF from entering catagen, 
and, thus reveals a delay in HF cycling. At P20 the EGFRΔep HFs still arrest in 
anagen, while in wild-type skin degradation of HF is already completed and they rest 
in telogen (Fig. 8A). 
 
Figure 8 ǀ Histological analysis of back skin of 
EGFRfl/fl and EGFRΔep mice at different days 
after birth (P8, P10, P17, P19, P20; A-C). 
Analysis of hair follicle (HF) length in back skin 
labeled with DAPI (A). Quantitative analysis of 
proliferating (B) and apoptotic cells per HF (C). 
Data represent mean  ± SEM. *p ≤ 0.05, 
**p ≤ 0.005, ***p ≤ 0.0005 
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Moreover, double staining for proliferating and apoptotic cells in hair follicles 
was performed (Fig. 9). Interestingly, the number of proliferating cells in EGFRΔep HF 
is significantly lower at all time-points compared to EGFRfl/fl (Fig. 8B, 9) which might 
explain the reduced HF length in EGFRΔep skin (Fig. 8A). Moreover, whereas the 
number of apoptotic cells in wild-type HF increases at P10 and declines continuously 
in accordance with A/C transition and entry of the resting phase/ telogen, the number 
remains nearly the same in EGFRΔep (Fig. 8C, 9). These results demonstrate that 
EGFR is necessary for proper progress of HF cycle due to regulation of proliferation 
and apoptosis. 
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Figure 9 ǀ Skin sections of EGFRfl/fl and EGFRΔep mice at different days after birth (P8, 
P10, P17, P19, P20).  Quantification of apoptotic cells, using ApopTag Detection Kit, and of 
proliferating cells, using Ki67 staining. 
 
2. EGFRΔep mice display strong infiltration of immune cells 
 
The alternating growth and degradation phases of HFs during the hair cycle 
are accompanied by attraction of different immune cells (Ito, 2010; Ito et al., 2008). 
Histological analysis of skin sections from mice with mutations in the EGFR signaling 
pathway demonstrated increased skin inflammation. To address if the inflammation 
found in EGFR mutant skin is due to alterations of HF morphogenesis or cycling 
histological analysis was performed. Back skin samples of EGFRΔep and EGFRfl/fl 
mice were isolated at different days after birth (P8, P10, P17, P19) to exhibit immune 
cell infiltration in a time dependent manner. O.C.T. embedded sections were double-
stained with FITC and PE labeled antibodies detecting proteins like MHC class II and 
F4/80, GR1, CD11b, CD11c, CD3ε and langerin. Quantitative analysis revealed a 
significant increase of cells expressing MHC II and/or F4/80, which are macrophages 
respectively, in mice lacking EGFR in epidermis at all time-points (Fig. 10A). 
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Moreover the number of cells expressing GR1 and/or CD11b, which are myeloid 
granulocytes, monocytes and early hematopoietic dendritic progenitor cells 
respectively, was always higher in EGFRΔep skin, especially at late stages (P17, P19) 
(Fig. 10B). Accordingly, also the infiltration of CD11c+ and/or MHC II+ cells, 
representing dendritic cells, was always increased in EGFRΔep mice compared to 
their littermate controls with a peak at postnatal day 10 (Fig. 10C). No significant 
difference was detected in CD3ε+ cells, which are T-cells respectively, and langerin+ 
cells infiltration, except that at P17 Langerhans cells and at P19 CD3ε+ cells were 
significantly increased in EGFRΔep mice compared to the control (Fig. 10D). 
Taken together these results show a strong infiltration of several immune cells 
in EGFRΔep mice during different stages of the hair follicle cycle. 
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Figure 10 ǀ Quantitative analysis of immune cells in EGFRΔep and EGFRfl/fl skin (A-D). 
MHC II+ and/or F4/80+ cells are significantly increased during the whole hair cycle (A). GR1+ 
and/or CD11b+ cell infiltration is also increased in EGFRΔep mice compared to EGFRfl/fl (B). 
Both the number of MHC II+ and/or CD11c+ cells is elevated in mice lacking EGFR (C). 
Numbers of T-cells and LCs are similar (D). Data represent mean ± SEM. *p ≤ 0.05, **p ≤ 
0.005, ***p ≤ 0.0005 
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3. Postnatal deletion of EGFR does not affect the number of epidermal 
Langerhans cells 
 
In vitro inhibition of ERK, a downstream target of EGFR, results in enhanced 
expression of stimulatory and adhesion molecules by Langerhans cells, thereby 
improving their function (Fujita et al., 2007). To investigate if EGFR deletion affects 
the number of LCs, ear sheets from both EGFRΔep and EGFRΔepER mice and the 
respective littermate controls were stained for the surface proteins MHC II and 
langerin. 
While in EGFRΔep mice Langerhans cells seem to be decreased in number in 
epidermal ear sheets compared to EGFRfl/fl mice, no difference could be detected 
between EGFRΔepER and EGFRfl/fl mice (Fig. 11). A possible reason may be that 
deletion of EGFR is insufficient in these mice so that no difference can be seen in the 
number of Langerhans cells or that inflammatory phenotype is milder in mice where 
EGFR is deleted after birth compared to mice where EGFR is already deleted during 
embryogenesis. Furthermore, despite the fact that in vitro inhibition of EGFR 
improves Langerhans cell function (Fujita et al., 2007), the reduction of Langerhans 
cells in EGFRΔep mice suggests, that EGFR may be important for Langerhans cell 
regulation or recruitment. 
 
 
Figure 11 ǀ Quantification of LCs in 
EGFRΔep and EGFRΔepER mice. Histological 
analysis of Langerhans cells suggest a 
decrease in EGFRΔep ears, while Langerhans 
cells infiltration seems to be not affected in 
EGFRΔepER ears compared to respective 
littermate controls. Data represent mean 
± SEM. 
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4. Lack of epidermal EGFR affects TPA-dependent hyperplasia 
 
12-O-Tetradecanoylphorbol-13-acetate (TPA) is a diester of phorbol and a 
potent tumour promoter often employed to activate the signal transduction enzyme 
protein kinase C (PKC) (Niedel et al., 1983). Topical application of TPA on the mouse 
skin is a well-known model for an induction of oxidative stress, ROS production, 
cutaneous inflammation and subsequently occurring hyperplasia. The inflammatory 
process is characterized by a recruitment of inflammatory cells such as neutrophils 
by chemotactic factors to inflammatory regions and edema formation (Nakamura et 
al., 1998). 
As previously described conditional EGFR mice harbouring a Cre-transgene 
were treated with tamoxifen (TX) to induce EGFR deletion in the skin. By Western 
Blot the loss of EGFR protein of EGFRfl/fl K5-CreER mice (EGFRΔepER) in the 
epidermis upon TX treatment was proven (Fig. 12). 
 
Figure 12 ǀ EGFR is efficiently deleted in EGFRΔepER epidermis upon TX treatment. 
Western blot showing EGFR expression. Actin was used as a loading control. 
 
Subsequently the back skin was shaved and treated with the chemical 
carcinogen 12-tetradecanoyl-phorbol-13-acetate (10µg TPA/ 200µl acetone) for 
the following 3 days. Skin samples were prepared to investigate the skin morphology 
by hematoxylin/eosin staining (H&E). 
Histological analysis by H&E staining points out that the epidermis is thicker 
after the TPA treatment, however TPA-treated mutant mice – EGFRepER – display a 
less thick epidermis as compared with the treated controls (Fig. 13A). The general 
increase of epithelial cells induced by the tumour promoting TPA treatment seems to 
be prevented in keratinocytes lacking EGFR, which could underline the importance of 
EGFR as a survival factor under stressful conditions. 
 
Actin
EGFR
- +     +      +      +     - - +     - - - +
EGFRfl/fl
Cre
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Figure 13 ǀ TPA-mediated increase of epidermal thickness (A-C). Comparison of 
epidermal thickness of TPA-treated (C) and untreated (B) EGFRfl/fl and EGFR∆epER skin, H&E 
staining. 
 
5. EGFR deficiency reduces TPA-dependent epidermal apoptosis and cell 
proliferation 
 
Furthermore, skin sections from TPA-treated mice were analysed with TUNEL 
method, utilizing an anti-digoxigenin antibody conjugated to a Fluorescein reporter 
molecule, quantifying all apoptotic cells in the epidermis. However during 
41 
 
differentiation keratinocytes extrude the nucleus and are TUNEL positive. TPA-
mediated stress induces apoptosis in both EGFRfl/fl and EGFRΔepER mice, as 
expected, but interestingly the number of apoptotic cells was significantly decreased 
in EGFRΔepER mice compared to EGFRfl/fl mice (Fig.14A). They also showed a lower, 
albeit non-significant, number of Ki67+ cells upon TPA treatment (Fig.14B). This 
impaired proliferation suggests the reduced epidermal thickness upon TPA 
treatment. However, the reduction in apoptotic cells was rather unexpected as it was 
demonstrated that EGFR is a survival factor for epidermal cells in skin tumors (Sibilia 
et al., 2000). 
 
  
Figure 14 ǀ Reduced apoptosis after TPA treatment in EGFRΔepER mice (A) and Ki67+ 
cells (B). Quantitative analysis of apoptotic cells in skin sections isolated from untreated (UT; 
n= 2) and TPA-treated (TPA) mice (n= 4/5). Quantification of Ki67+ cells in skin sections 
isolated from untreated (UT; n=2) and TPA-treated (TPA) mice (n=6). Data represent mean ± 
SEM. *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005 
 
6. Lack of EGFR affects TPA-mediated activation of various signaling 
pathways 
 
Next, molecular changes involved in the signaling pathway downstream of 
EGFR in TPA treated keratinocytes were investigated. Therefore epidermal cells 
were isolated from EGFRΔepER and EGFRfl/fl mice, processed to protein lysates and 
analyzed by Western Blot. Since no difference in EGFR protein level was detected in 
these total epidermis lysates (data not shown), keratinocytes of EGFRfl/fl and 
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EGFRΔep mice were isolated and cultured until they reached 80% confluence. Cells 
were starved for 24hr and incubated either with 100ng/ml TPA or 20ng/ml EGF and 
100ng/ml TPA for 5 min. Western Blot analysis revealed that EGFR was efficiently 
deleted in EGFRΔep epidermal cells (Fig. 15). While TPA treatment has no impact on 
AKT, pNFκB and p-p38 activation in wild type keratinocytes, pERK1/2 protein level is 
increased upon TPA treatment. Moreover, both TPA-mediated AKT and ERK1/2 
activation is increased compared to wt, but TPA-mediated activation of NFκB and 
p38 is independent of EGFR signaling in EGFRΔep epidermal cells. The strong TPA-
mediated activation of AKT as well as ERK1/2 in keratinocytes lacking EGFR 
indicates a suppressive role of EGFR. 
 
 
Figure 15 ǀ Western blot analysis of 
keratinocytes stimulated in vitro 
with TPA or TPA and EGF. Analysis 
of phosphorylation of AKT, Erk1/2, 
NFκB and p38 in protein lysates from 
keratinocytes isolated from EGFRfl/fl 
and EGFRΔep mice. Cultured 
keratinocytes were starved for 24 hours 
prior stimulation with TPA or TPA and 
EGF. 
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7. EGFR regulates infiltration of several immune cells after TPA treatment 
 
Keratinocytes are responsible for skin homeostasis including the precise 
regulation of immune cell attraction to the leason by secretion of chemokines 
(Schafer and Werner, 2008). As mice defective in the EGFR pathway display skin 
inflammation, and due to the fact that it was shown that EGFR signaling affects the 
expression of different cytokines and chemokines in vitro (Pastore et al., 2005) EGFR 
signaling seems to play an important role in regulating immune responses of the skin. 
As described above topical application of TPA on mouse skin is a well-known 
model for induction of cutaneous inflammation. To establish in which manner the lack 
of EGFR in the epidermis has an impact on the immune cell attraction, the skin of 
EGFRΔepER and EGFRfl/fl mice was treated with 10μg TPA/ 200μl acetone for 3 
consecutive days. The O.C.T. embedded sections were double-stained with FITC 
and PE labeled antibodies detecting proteins like MHC class II and F4/80, GR1 and 
CD11b, CD11c and MHC class II, and CD3ε and langerin. Three independent 
batches were analyzed. 
Generally, quantitative analysis of immune cell infiltration in TPA-untreated 
skin lacking the EGF receptor exhibited a lower number of macrophages and 
dendritic cells (Fig. 16A, C) compared to the control, contradicted to what was shown 
before (Fig.10A, C). One possible explanation could be that EGFR deletion in skin 
was insufficient, which could stretch the results. In wild type skin, TPA promotes a 
significant decrease of cells expressing MHC II (Fig. 16A), which could be a marker 
for macrophages, B-cells, LC and DC, CD11b, which are monocytes, and 
GR1/CD11b (Fig. 16B). In addition, a significant decrease of CD3ε+ cells, which 
represent T-cells respectively, was detected (Fig. 16D). In EGFRfl/fl skin the attraction 
of several immune cells like macrophages, expressing MHC II and F4/80 (Fig. 16A), 
myeloid granulocytes, GR1+ cells (Fig. 16B), DCs, expressing CD11c and MHC II 
(Fig. 16C), as well as Langerhans cells (Fig. 16D) seems to be TPA dependent. 
In EGFRΔepER skin, TPA application resulted in a significant rise of 
macrophages (F4/80+, MHC II+/ F4/80+) (Fig.16A), monocytes (CD11b+), early 
hematopoietic dendritic progenitor cells (GR+/CD11b+) (Fig.16B), DC (CD11c+) 
(Fig. 16C), and a decrease of T-cells (Fig. 16D) compared to the untreated 
EGFRΔepER skin. Loss of EGFR in the skin does not affect TPA-mediated LCs 
infiltration (Fig. 16D). 
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These results show that EGFR regulates infiltration of several immune cells 
after TPA treatment which may indicates its regulatory role in the immune response 
during tumor promotion. 
  
  
Figure 16 ǀ Quantitative analysis of immune cell infiltration (cell/ 0,1mm2) of untreated (UT) and 
TPA treated (TPA) back skin samples of EGFRΔepER and EGFRfl/fl mice (A-D). Quantification of 
MHC II+ and/or F4/80+ cells (A), GR1+ and/or CD11b+ cells (B), MHC II+ and CD11c+ cells (C), and of 
CD3ε+ or langerin+ cells (D) in EGFR∆epER  and EGFRfl/fl skin. Data represent mean ± SEM. *p ≤ 0.05, 
**p ≤ 0.005, ***p ≤ 0.0005 
 
8. Inflammation in EGFR deficient mice is not sufficient to induce 
papillomas 
 
Inflammation and carcinogenesis are tightly linked. The inflammatory 
microenvironment plays a very important role, because the formation and 
progression of tumors is dependent on the reactive stroma surrounding the cancer 
lesion (Moore et al., 1999). Mice lacking EGFR in epidermis display a general basic 
inflammation which might promote tumorigenesis. To investigate if the inflammation 
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found in EGFR mutant skin is sufficient to induce cancer, metabolic activation of 
procarcinogens was induced by a single topical application of 10µg DMBA, a 
common carcinogen, in seven week old mice (EGFRfl/fl, EGFRΔepER). Tumor 
development was monitored for 30 weeks leading to the conclusion that the 
inflammation resulting from loss of EGFR in the epidermis is not sufficient to induce 
papillomas after initiation (data not shown). 
 
9. Induced inflammation in EGFRΔepER mice results in an earlier tumor 
occurrence 
 
However, if DMBA treatment was followed by continuous application of TPA 
according to 2-stage skin carcinogenesis also EGFRΔepER mice developed tumors. 
For investigating the tumor incidence (= percentage of animals with tumors) and the 
tumor multiplicity (=numbers of tumors/mouse), seven weeks old EGFRfl/fl and 
EGFRΔepER mice were treated with a single subcarcinogenic dose of 10µg DMBA. 
After one week without treatment, tumor promotion was continued by TPA application 
twice a week for a time span of 30 weeks (Fig. 17).Interestingly, in contrast to what 
was published before (Casanova et al., 2002; Sibilia et al., 2000) mice lacking EGFR 
in the epidermis developed tumors earlier than wt controls. 
 
 
Figure 17 ǀ Schematic illustration 
of two-stage carcinogenesis in 
EGFRΔepER mice. Tumor induction 
via DMBA at week 7 and promotion 
by TPA twice a week from week 9 
on was accomplished. Tamoxifen 
was applied twice a week. 
Mice lacking EGFR in the epidermis revealed an earlier tumor occurrence and 
the first tumor was detected on EGFRΔepER back skin eight weeks after the beginning 
of tumor promotion by TPA application. Moreover, all EGFRΔepER mice had developed 
tumors after 12 weeks; whereas 90% of EGFRfl/fl mice were tumor free at this time 
point and three weeks later 70% of EGFRfl/fl mice still had not developed any 
papillomas. Only after 17 weeks of promotion with TPA all remaining control mice 
evolved tumors at their back skin (Fig. 18A). These data suggest that in a 2-stage 
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skin carcinogenesis model genetic deletion of EGFR in keratinocytes could promote 
tumor formation. Further analysis of total and average tumor size reveal that 
EGFRΔepER mice papillomas had an initial growth advantage towards those evolving 
in EGFRfl/fl mice. However, at late time-points (week 20) tumors from mice lacking 
EGFR in the epidermis stopped growing and entered tumor stasis, whereas 
papillomas from wild-type mice constantly increased in size. 
In summary, it can be stated that in EGFRΔepER mice early tumor formation 
might result from the skin inflammation, triggered by the absence of EGFR in 
epidermal cells (Fig. 18A). However, lack of EGFR negatively affects tumors volumes 
compared to tumors in wild-type controls (18 B, C). 
 
 
Figure 18 ǀ Tumor development in 
TPA treated mice. Monitoring of tumor 
occurrence in EGFRfl/fl and EGFRΔepER 
mice during 2-stage carcinogenesis 
(A). Analysis of total tumor size (B) and 
average tumor volume (C) per mouse 
measured every five week for a total of 
30 weeks (n= 5-7).  
 
Data represent mean ± 
SEM. *p ≤ 0.05, **p ≤ 
0.005, ***p ≤ 0.0005 
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10. Tumors lacking EGFR display a higher proliferation 
 
EGFR is overexpressed in many of tumors (Gullick, 1991; Habib et al., 2003) 
and EGFR signaling significantly affects survival of cancer cells (Lichtenberger et al., 
2010; Sibilia et al., 2000). Moreover, dn EGFR tumors display a higher apoptosis 
rate, but no significant change in their proliferation rate (Casanova et al., 2002). 
Tumors from both EGFRfl/fl and EGFRΔepER back skin were isolated after 25 weeks of 
TPA treatment to investigate EGFR-dependent tumor survival in the skin. 
Furthermore, double staining for apoptotic and proliferating tumor cells were 
performed to investigate if TPA application has an impact on central and marginal 
tumorigenic tissue of EGFRΔepER and EGFRfl/fl mice. 
Histological analysis of EGFRfl/fl suggests that tumors reveal a higher 
proliferation rate in the tumor center (Fig. 20A, B), and that in the marginal tumor 
tissue primarily apoptotic cells are detected (Fig. 21A/B). Interestingly, tumors lacking 
EGFR display strong proliferation, but less apoptosis in their central region (Fig. 20C) 
compared to wt controls after TPA treatment. Furthermore, EGFRΔepER marginal 
tumor tissue reveals no obvious difference in the apoptosis rate compared to 
EGFRfl/fl. Generally marginal tumor tissue derived from EGFRΔepER shows a low 
number of proliferating and a high number of apoptotic cells (Fig. 21C). 
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Figure 19 ǀ Macroscopic 
appearance of back skin 
treated with TPA. 
EGFRfl/fl (A, B) and EGFRΔepER 
(C) back skin treated with the 
tumor promoting agent TPA for 
25 weeks. Tumor volumes in 
EGFRfl/fl (B) mice are bigger 
than in EGFRΔepER mice. 
 
 
Figure 20 ǀ Immunohistological analysis of central tumorigenic tissue in EGFRfl(fl and 
EGFRΔepER mice (A-C). Double staining with Ki67 antibody and ApopTag Detection Kit of 
tumor sections originating from EGFRfl/fl (A, B) and EGFRΔepER mice (C). 
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Figure 21 ǀ Immunohistological analysis of marginal tumorigenic tissue in EGFRfl(fl and 
EGFRΔepER mice (A-C). Double staining with Ki67 antibody and ApopTag Detection Kit of 
tumor sections originating from EGFRfl/fl (A, B) and EGFRΔepER mice (C). 
 
11. Regulation of immune cell composition by EGFR in tumor tissue  
 
 The process of wound healing, chronic inflammation and tumor development 
are very closely linked, not only by molecular but also by cellular parallels (Schafer 
and Werner, 2008). To gain insights into EGFR-dependent immune regulation in 
cancer, two EGFRfl/fl mice and one EGFRΔepER mouse were analyzed, which were 
treated with TPA for 25 weeks after DMBA induction. Figure 22 exhibit the immune 
cells composition present in the different regions (central, marginal) of a tumor. Skin 
samples were divided in tumor free tissue, which represents parts of the skin nearby 
the tumor, tumor center and tumor edge. Sections were double-stained with FITC 
and PE labeled antibodies detecting surface proteins like MHC class II and F4/80 
(Fig. 22A-C), CD3ε and langerin, (Fig. 22D-F), GR1 and CD11b (Fig. 22G-I), and  
CD11c and MHC class II (Fig. 22J,K). Due to too less samples CD11c and MHC 
class II analysis of the tumor edge was impossible. 
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Figure 22 ǀ Immunohistological quantification of immune cells in tumor free tissue, 
central and marginal tumor tissue (A-K). Isolated tumors from EGFRfl/fl and EGFRΔepER 
mice were stained for MHC II+ and/or F4/80+ cells (A-C), CD3ε+ or langerin+ cells (D-F), GR1+ 
and/or CD11b+ cells (G-I) and for MHC II+ and/or CD11c+ cells (J, K). Immune cells from 
tumor free tissue (A, D, G, J), central tumor tissue (B, E, H, K) and marginal tumor tissue (C, 
F, I) were quantified (n= 1-2). Data represent mean ± SEM. 
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Generally, quantitative analysis of MHCII+ cells and macrophages 
(MHCII+/ F4/80+) in tumor tissue might be genotype-dependent (Fig. 22A-C). More 
precisely, it was shown that in EGFRfl/fl tumors MHC II+ cells and the macrophages 
population of central differs from marginal tumor tissue. The amount of immune cells 
remains low in the tumor center (Fig. 22B) and is increased at the edge (Fig. 22B). It 
might be that the immune cells were attracted to the edge of EGFRfl/fl derived tumor. 
In EGFRΔepER papillomas MHC II+ cells and macrophages were equally spread all 
over the tumor tissue. 
The presence of T-cells (CD3ε+) and LC (langerin+) in tumor and tumor free 
tissue was also quantified (Fig. 22D-F). In wt mice only very few T-cells and LC were 
located within the tumors while many T-cells and LCs were located in tumor free 
tissue. Interestingly, while there were less LCs and T-cells in the tumor-free tissue of 
EGFR mutants mice compared to littermate controls, their numbers were significantly 
higher within the tumors (Fig. 22E/F). 
Quantification of granulocytes (GR1+), monocytes (CD11b+) and early 
hematopoietic dendritic progenitor cells (GR1+/ CD11b+) (Fig. 22G-I) revealed that 
EGFRΔepER tumor free tissue displayed two-fold less cells than wt specimen 
(Fig. 22G). However, in wt tumors granulocytes, monocytes and early hematopoietic 
dendritic progenitor cells were less present than in tumor free tissue and equally 
spread all over the tumor tissue. In comparison, in papillomas from mutant mice the 
immune cells were concentrated at the tumor center (Fig. 22H), and no difference in 
immune cell abundance was detectable compared to the center of wt tumor tissue. 
Moreover, in tumor tissue lacking EGFR the amount of these immune cells was 
decreased at the tumor edge compared to the control (Fig. 22I). 
As mentioned before due to too less samples, the analysis of DC 
(MHCII+/ CD11c+) infiltration in the tumor edge was impossible. Nevertheless, I found 
that DC members were dramatically decreased in EGFRΔepER derived central tumor 
tissue compared to the control (Fig. 22K). 
In conclusion, the composition of the immune cell infiltrate is different in tumor 
tissue as well as the surrounding skin of wild-type and EGFRΔepER mice. 
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Discussion 
 
The EGFR, one out of 4 receptors of the EGFR family, appears to be one of 
the most important and fascinating growth receptors. Its activation by multiple 
extracellular binding factors is responsible for many complex downstream pathways 
regulating a variety of cellular functions including proliferation, survival, migration and 
differentiation. Although the function of EGFR is still a widely uninvestigated field in 
science the receptor gains in importance in clinical applications and is therefore in 
the focus of many research groups. The proper expression of EGFR on the cell 
surface as well as its proper signal transduction in different organs and cell types is 
determining prenatal and postnatal development. EGFR affects premature 
differentiation of keratinocytes and influences osteoblast and chondrocytes 
differentiation negatively (Sibilia et al., 2007).  
Many studies in mice lacking EGFR have confirmed that the EGFR signaling 
network is essential for skin development and its appendages (Sibilia et al., 2003; 
Sibilia and Wagner, 1995). Inhibitors of EGFR and ErbB2 cause suppression of hair 
growth in wt mice, and hair follicles remain in anagen (Mak and Chan, 2003). Mice 
with an epidermis-specific deletion of EGFR fail entering anagen-catagen-transition, 
the length of hair follicles is highly reduced, and, thus reveals a delay in HF cycling. 
Furthermore, I was able to show that in EGFR mutants proliferation of transit-
amplifying cells is significantly decreased in hair follicles during anagen compared to 
their littermate controls. Interestingly, loss of EGFR causes a higher and constant 
level of apoptosis in HF of EGFR deficient skin. Evidence that EGFR mutant mice 
loose most hair follicles over time came from the analysis of hEGFRKI/KI mice, which 
display a progressive HF degeneration which might be by the massive inflammatory 
infiltrate in the skin, consisting mainly of macrophages, lymphocytes, neutrophils and 
multinucleated giant cells (Sibilia et al., 2003). Histological analysis of skin biopsies 
from EGFRΔep mice exhibited a strong inflammation of both epidermis and dermis. 
Preliminary data have revealed that macrophages, myeloid granulocytes, monocytes 
and dendritic cells are significantly increased throughout the different stages of HF 
morphogenesis and HF cycle. Although previous unpublished results of the lab had 
shown that in the epidermis of EGFR deficient mice there were a large number of 
Langerhans cells and αβT-cells. However, quantification at different time points of 
hair follicle morphogenesis elucidated no significant difference in the dermis or 
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epidermis. Nevertheless, CD3ε+ T-cells are significantly increased in EGFRΔep skin 
biopsies at postnatal day 19 only, while Langerhans cells infiltration is exclusively 
increased at postnatal day 10. The results obtained in this study confirmed the strong 
influence of EGFR balancing hair follicle morphogenesis and cycle, and immune 
responses of the skin. 
EGFR plays a critical role in inflammation and epithelial tumorigenesis, two closely 
linked cellular processes. Previous studies confirmed mesenchyme-epithelium 
alterations and increased inflammation by abrogation of EGFR function in the skin 
(Luetteke et al., 1993; Murillas et al., 1995) and EGFR overexpression in epidermal 
tumors (Casanova et al., 2002; Hunts et al., 1985). Investigation of the functional 
effect of EGFR signaling on keratinocyte proliferation and survival revealed that 
EGFR deficiency reduces TPA-dependent hyperplasia as well as epidermal 
proliferation and apoptosis. Consistent with the decreased level of apoptosis in 
EGFR deficient skin, in vitro analysis of transgenic keratinocytes examine, that EGFR 
depletion enhances TPA-mediated AKT activity, although further analysis of mice 
genetically modified for EGFR expression indicate that EGFR acts as survival factor 
in epidermal tumors by initiation of the anti-apoptotic AKT pathway (Sibilia et al., 
2007). Surprisingly, TPA-mediated ERK1/2 activation is EGFR dependent, despite 
the decreased proliferation rate. NFκB and p38 protein expression seemed to be 
EGFR independent. Due to the fact that EGFR signaling influences the expression of 
different cytokines and chemokines in vitro (Pastore et al., 2005), EGFR potentially 
plays an important role in the regulation of the immune response during tumor 
promotion. There is increasing evidence that the EGFR pathway has an important 
impact on the inflammatory reactions in the skin in presence of a tumor promoting 
agent. The results in this study demonstrate that EGFR deficiency increases TPA-
dependent attraction of monocytes, early hematopoietic dendritic progenitor cells, T-
cells and dendritic cells. Furthermore, TPA-induced Langerhans cell and 
macrophage attraction is EGFR independent. However, the effect of EGFR signaling 
on TPA-dependent expression of several chemokines and cytokines by keratinocytes 
and its influence on the inflammatory response needs to be further examined. 
Moreover, I could show that the basic inflammation found in EGFR mutants is 
not sufficient to induce and/or promote papillomas. However, upon 2-stage skin 
carcinogenesis with DMBA/TPA, tumor formation does occur in EGFR mutant mice. 
Interestingly, in contrast to what was published before (Casanova et al., 2002; Sibilia 
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et al., 2000) EGFR mutant mice develop tumors earlier than wt controls. More 
precisely, it could be shown that tumor formation might result from skin inflammation 
triggered by the absence of EGFR in epidermal cells. Importantly, the analysis of 
total and average tumor size reveals growth advantage of papillomas from 
EGFRΔepER mice towards those evolving in EGFRfl/fl mice in the early stages of tumor 
formation. However, tumors from EGFR mutant mice enter tumor stasis and remain 
rather small, whereas papillomas from wt mice constantly increase in size. Additional 
studies are required to determine the influence of EGFR on tumor development. 
Analysis of wt tumors and those derived from EGFR deficient mice revealed 
that in the central tumor tissue of EGFR mutant mice the proliferation rate is 
increased while apoptosis is decreased in comparison to wt controls. In marginal 
tumor tissue no obvious difference in the apoptosis rate was perceived. A very 
interesting finding is that the analysis of central and marginal tumor tissue revealed a 
different subset of immune cells in wt and EGFR mutant mice: the number of 
dendritic cells and macrophages is decreased in tumor tissue and they are spread all 
over it compared to controls. The number of both T-cells and Langerhans cells in 
papillomas lacking EGFR is much higher than in papillomas of wt, while the 
abundance of granulocytes, monocytes and early hematopoietic dendritic progenitor 
cells reveals no differences compared to controls. These results suggest that 
expression of EGFR in tumor tissue plays a critical role in the regulation of immune-
cell infiltration. 
Additional studies are required to determine how the complex EGFR signaling 
network regulates these responses to influence inflammation and tumor 
development, respectively. Deeper understandings of the impact of EGFR on skin 
inflammation will support the clinical progress of developing anti-EGFR therapies in 
skin cancer, as development of inflammatory skin eruptions and abnormal hair 
growth is often therapy-limiting. 
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Materials and Methods 
 
Mouse strains 
Conditional EGFR mice (EGFRfl/fl) (Natarajan et al., 2007) were crossed to K5-Cre 
(Tarutani et al., 1997) and K5-CreERT (Indra et al., 1999) transgenic mice to 
generate mice in which EGFR is constitutively deleted in the basal layers of the 
epidermis starting from embryonic day 14,5 (EGFR∆ep), or mice in which EGFR 
deletion could be induced by administration of tamoxifen (EGFR∆epER), respectively. 
EGFR-/- (Sibilia and Wagner, 1995) and EGFRwa2/+ and EGFRwa2/wa2 were available in 
the laboratory. The Wa-2 EGFR allele contains a T-to-G transversion mutation in the 
sequences encoding the tyrosine kinase domain resulting in a substitution of a 
glycine for a highly conserved valine at position 743 in the third kinase subdomain. 
The ability of wa2 EGFR to phosphorylate an exogenous substrate is reduced by > 
90% compared with that of the control receptor (Luetteke et al., 1994). 
Mice were kept in the animal facility of the Medical University of Vienna in 
accordance with institutional policies and federal guidelines. 
 
Tamoxifen treatment 
To induce EGFR deletion K5-CreERT transgenic EGFRfl/fl mice were injected 
intraperitoneally with 1 mg of tamoxifen per 25g body weight (Sigma; sunflower seed 
oil/ethanol mixture (10:1) at 10mg/ml) per day on 5 consecutive days and then twice 
a week for maintenance. Deletion efficiencies were analysed by Western blot 
analysis. 
 
Two-stage carcinogenesis and measurement of rising tumors 
7-week-old EGFR∆epER mice and littermate controls were treated with 10µg DMBA. 
After one week intermission TPA treatment (5µg per mouse and day) was initiated 
and continued consequently twice a week. Tumors were measured with a digital 
caliper every second week.  
 
Isolation and culture of mouse keratinocytes 
Shaved mice were skinned and the subcutaneous tissue was scraped off. Small 
pieces of the skin were placed hairy side up onto 0,8% Trypsin/PBS and incubated  
for 1 hour at 37°C. The epidermis was separated from the dermis and placed into 
56 
 
DNAse-Medium (low calcium medium containing 8% FCS and 250µl/ml DNAseI and 
incubated for 20 min at 37°C shaking. The suspension was filtered through a 70µm 
cell strainer (Becton Dickinson) & cells were collected by centrifugation. Cells were 
washed once with DNaseI-medium & then seeded at a density of 6x106 cells/100mm 
dish onto vitrogen-fibronectin coated dishes or were directly processed to protein 
lysates or RNA. Incubate cells at 32°C, 5% CO2 and change medium every 2-3 days. 
For in vitro deletion of EGFR keratinocytes isolated from EGFRΔepER mice were 
cultured in medium containing 100nM tamoxifen. When cells reached 80% 
confluency cells were starved for 24hr, and stimulated with 100ng/ml TPA or 
100ng/ml TPA/ 20ng/ml EGF for 5 minutes, they were kept on ice, washed properly 
with ice cold PBS and were processed to protein lysates or RNA. 
 
Preparation of epidermal protein lysates and Wester Blot analysis 
Epidermal cells kept on ice were washed with PBS and lysed with buffer containing 
50mM Hepes pH 7,3, 150mM NaCl, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 
10mM Na2P2O7, 10µm/ml Aprotinin, 10µm/ml Leupeptin, 25mM NaF, 1mM NaVO3, 
1mM PMSF, 20mM PNPP, H2O; and centrifuged 10 min at full speed at 4°C. 40µg 
protein were separated by SDS-PAGE and transferred to PVPF membranes 
(Millipore). Western Blot was performed according to standard procedures (Sibilia et 
al., 2000) using the following antibodies: anti-EGFR (Cell signalling #2232; Santa 
Cruz Biotechnology); anti-phospho-AKT and anti-AKT (Cell signalling #4051); anti-
phospho-NFκB and anti-NFκB; anti-phospho-p38 and anti-p38; anti-phospho-ERK1/2 
and anti-ERK1/2 (NEB #9101L, ); anti-actin and anti-tubulin (Sigma), and secondary 
antibodies from Jackson laboratories. 
 
Isolation of genomic DNA 
3-5 mm of mouse tail, small pieces of tissue or cell pellets were incubated overnight 
in 500µl Tail buffer (50 mM Tris-HCl pH8; 100mM EDTA; 100mM NaCl; 1% SDS and 
0,5 mg/ml proteinase K) at 55°C. 200µl of saturated (6M) NaCl were added, the 
suspension was mixed and centrifuged 5 min at full speed. The supernatant was 
transferred to a new tube, 500µl isopropanol was added, everything was mixed 2 min 
on the shaker and again centrifuged for 5 min at full speed. After washing the pellet 
with 1ml 70% ethanol the DNA pellet was air dried. Finally, the DNA pellet was 
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resuspended in 300-400µl of TE (10mM Tris pH 7,6; 1mM EDTA) depending on the 
pellet size. 
 
Restriction digest of genomic DNA 
3µl genomic DNA were digested with Hind lll restriction enzyme (1,5µl Hind lll; 
1,5µl 10x restriction buffer B; 9µl H2O) and separated by electrophoresis on a 0,8% 
agarose gel. 
 
Detection of the CRE transgene by PCR 
1µl DNA solution and 24µl master mix, containing 2,5µl GB buffer; DMSO; dNTPs 
(10mM); primer K5Cre1 (1,2µM); primer K5Cre2 (1,2µM); 11,25µl H2O; and 
0,25µl Taq polymerase (5U/µl) was mixed for analysing the mouse genotype. The 
following primers were utilized to detect the Cre transgene: 
K5Cre1: (24bp) 5’ CAT ACC TGG AAA ATG CTT CTG TCC 3’ 
K5Cre2: (24bp) 5’ CAT CGC TCG ACC AGT TTA GTT ACC 3’ 
 
Thermal cycle conditions: 
94°C – 2 min 
35x (94°C – 30 sec, 53°C – 45 sec, 65°C – 1 min) 
65° - 5 min 
4°C ∞ 
PCR products were separated on a 2,5% agarose gel. K5Cre positive mice show a 
500bp band.  
 
Total RNA isolation and RT analysis 
Total RNA from epidermis, cultured epidermal cells, were isolated with TRIzol 
Reagent (Invitrogen). cDNA synthesis was performed with SuperScript First-Strand 
Synthesis System (Invitrogen) according to the manufacturer’s instructions. qRT-PCR 
was performed using the LightCycler FastStart DNA MasterPLUS SYBR Green I kit 
together with LightCycler 2.0 System (Roche).  
 
Histological analysis 
Skin biopsies were embedded in OCT and cryopreserved or fixed in 4% 
paraformaldehyde and embedded in paraffin and cut into 5µm section. Sections were 
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deparaffinized with xylene, rehydrated in an ethanol series (100%x2, 90%, 80%, 
70%, 30%) and incubated in water as long as necessary. In case of cryosections, the 
slides were incubated in ice cold acetone at -20°C for 20min, air dried and washed 
with PBS. 
For hematoxylin/ eosin staining the slides were incubated 5 min in freshly filtrated 
hematoxylin, washed 3 times in water, dipped into HCl water for 3-5 seconds and 
again washed 2 times. After an ethanol series (30%, 70%, 80%) the sections were 
incubated in eosin solution for max. 45 seconds. Then the samples were further 
dehydrated (90%, 100% ethanol and xylem) and mounted with Entellan. 
For Ki67 staining the sections were incubated in an antigen retrieval solution (DAKO) 
in the microwave for 20 min and were washed 2 times with PBS. Next the slides were 
blocked with 10% goat serum/ PBS for 20 min and incubated with Ki67 antibody 
(1:1000, Novacastra) at 4°C over night. In the following steps the slides were washed 
with PBS, incubated with the secondary antibody anti-rabbit Alexa594 (1:5000; 
Jackson Laboratories) for 1 hour and washed again. Biopsies were counterstained 
with Hoechst (1:1000) for 20 min and mounted with Fluoprep and were stored in the 
dark. 
For detection of various immune cells, sections were blocked with 10% goat 
serum/ PBS for at least 20 min at RT. Afterwards sections were washed with PBS 
and were incubated with antibodies from Biolegend diluted in 2% BSA/ PBS over 
night at 4°C: 
 MHC class II–PE (1:300) / F4/80-FITC (1:100) 
 GR1-PE (1:200) / CD11b-FITC (1:100) 
 CD11c-PE (1:200) / MHC class II-FITC (1:150) 
 CD3ε-PE (1:100) / Langerin-FITC (1:400) 
In the following steps the biopsies were stained with Hoechst (1:1000) for 20 min and 
mounted with Fluoprep and were stored in the dark. 
Images were obtained with a Nikon eclipse 80i microscope; histomorphometric 
analysis was performed with Lucia software. 
 
ApopTag® Fluorescein In Situ Apoptosis Detection Kit and Ki67 staining 
Cryo sections were air dried for 5 min, then fixed with 1% paraformaldehyde in PBS 
for 10 min and washed two times with PBS for 5 min. All this steps were done at RT. 
The slides were post fixed with ethanol-glacial acid (2:1) for 5 min at -20°C. They 
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were washed again twice with PBS for 5 min at RT. The following incubation steps 
were performed in a humid chamber. Sections were incubated with equilibration 
buffer for 5 min at RT and afterwards with TdT Enzyme solution (70% Reaction 
Buffer; 30% TdT Enzyme) for 1 hour at 37°C according to the manufacturer’s 
suggestion (ApopTag® Fluorescein In Situ Apoptosis Detection Kit, Millipore). 
Sections were further incubated with the Stop/Wash Buffer for 10 min at RT and 
finally they were washed three times with PBS for 1 min. 
Biopsies were blocked with 10% goat serum/PBS for 20 min at RT, incubated with a 
1:100 dilution rat-αmouse-Ki67 (DAKO, Clon Tec 3) in 2% BSA/PBS at 4°C over 
night, washed with PBS, incubated with the secondary antibody goat-αrat-Alexa594 
(Jackson Laboratories; 1:500 in 2% BSA/PBS) for 1 hour at RT and washed again. 
Finally, sections were incubated with Anti-Digoxigenin Conjugate for 30 min at RT, 
washed four times with PBS and counterstained with DAPI or HOECHST and were 
mounted with Fluoprep. 
 
Epidermal ear sheet preparation and staining 
Ear sheets were separated, placed hairy side up onto 3,8% ammoniumthiocyanate/ 
PBS and incubated for  25 minutes at 37°C. Epidermis was separated form dermis, 
washed in PBS and fixed in acetone at RT for 15 minutes. Epidermal sheets were 
washed in PBS and stored in 2%BSA/PBS at -20°C. For epidermal sheet staining ear 
sheets were blocked with 10% goat serum/PBS for 20 minutes at RT and incubated 
with antibodies diluted in 2% BSA/PBS at 4°C over night (Langerin-FITC 1:400; MHC 
II-PE 1:300). The samples were counterstained with Hoechst for 20 minutes at RT 
and mounted hair side down with Fluoprep (Bio Merieux). 
 
Statistical methods 
Most of the experiments were repeated at least twice and done in triplicates. Data 
were evaluated using a Student’s two-tailed t-test. p<0,05 was taken to be 
statistically significant. 
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